lutetium has been researched along with Lymphoma, B-Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balkin, ER; Jia, F; Lewis, MR; Liu, D; Miller, WH; Ruthengael, VC; Shaffer, SM | 1 |
| Bal, CS; Gupta, SK; Malhotra, A; Sharma, A; Singla, S; Thakral, P; Vasisht, A; Yadav, MP | 1 |
| Abbas, N; Bruland, ØS; Dahle, J; Larsen, RH; Repetto-Llamazares, A | 1 |
| Campana, B; Forrer, F; Lohri, A; Maecke, H; Mueller-Brand, J; Oechslin-Oberholzer, C | 1 |
| Andrews, PM; Goldenberg, DM; Mattes, MJ; Michel, RB; Rosario, AV | 1 |
1 trial(s) available for lutetium and Lymphoma, B-Cell
| Article | Year |
|---|---|
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Rituximab; Treatment Outcome | 2012 |
4 other study(ies) available for lutetium and Lymphoma, B-Cell
| Article | Year |
|---|---|
Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Genes, bcl-2; Heterocyclic Compounds, 1-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lutetium; Lymphoma, B-Cell; Mice; Oligoribonucleotides, Antisense; Peptide Nucleic Acids; Peptides, Cyclic; Proto-Oncogene Mas; Radioisotopes; Radiometry; Tissue Distribution | 2014 |
An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Humans; Immunoconjugates; India; Lutetium; Lymphoma, B-Cell; Radioimmunotherapy; Radioisotopes; Rituximab | 2014 |
Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunotoxins; Iodine Radioisotopes; Lutetium; Lymphoma, B-Cell; Mice; Mice, Nude; Molecular Targeted Therapy; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Tetraspanins; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
Topics: Animals; Antibodies; Body Burden; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Radiation; Lutetium; Lymphatic Metastasis; Lymphoma, B-Cell; Mice; Mice, SCID; Radiation Dosage; Radioimmunotherapy; Radioisotopes; Radiometry; Radiopharmaceuticals; Relative Biological Effectiveness; Survival Analysis; Treatment Outcome | 2005 |